The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2024
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Sazhin A.V.

Pirogov Russian National Research Medical University

Khusyainova A.I.

Department of faculty surgery named after S.I. Spasokukotskyi, School of general medicine, Pirogov Russian National Research Medical University, Moscow, Russia

Petukhov V.A.

Department of faculty surgery named after S.I. Spasokukotskyi, School of general medicine, Pirogov Russian National Research Medical University, Moscow, Russia

Surgical management of diabetes mellitus: future outlook (part 3)

Authors:

Sazhin A.V., Khusyainova A.I., Petukhov V.A.

More about the authors

Journal: Endoscopic Surgery. 2017;23(3): 54‑64

DOI: 10.17116/endoskop201723354-64

Views: 1522

Downloaded: 21

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Sazhin AV, Khusyainova AI, Petukhov VA. Surgical management of diabetes mellitus: future outlook (part 3). Endoscopic Surgery. 2017;23(3):54‑64. (In Russ.)
https://doi.org/10.17116/endoskop201723354-64

Подписка 2025 (Endoscopic Surgery)
МСФ на ЯМ
Close metadata
Recommended articles:
Modern aspe­cts influencing the mana­gement of patients with papi­llary thyroid cancer. Piro­gov Russian Journal of Surgery. 2023;(12):89-94
Complex surgical treatment of recu­rrent post-injection abscess in a patient with systemic autoimmune disease. Piro­gov Russian Journal of Surgery. 2023;(12):123-133
Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Russian Journal of Evidence-Based Gastroenterology. 2023;(4):103-108
Features of lipid, carbohydrate meta­bolism and adiponectin secretion in pregnant women with abdo­minal obesity and arte­rial hype­rtension. Russian Bulletin of Obstetrician-Gynecologist. 2023;(6-2):101-106
Soli­tary fibrous tumor of the pleura with para­neoplastic Doege-Potter syndrome. P.A. Herzen Journal of Onco­logy. 2023;(6):50-56
Main causes of premature mortality due to obesity. Russian Journal of Preventive Medi­cine. 2023;(12):52-57
Pharmacogenetics of glucagon-like peptide-1 agonists in the treatment of type 2 diabetes mellitus. Russian Journal of Preventive Medi­cine. 2023;(12):95-100
Mastoid osteoma. Russian Bulletin of Otorhinolaryngology. 2023;(6):97-99
Opti­mal prevention of VTE in cancer surgery patients with impaired renal function. Piro­gov Russian Journal of Surgery. 2024;(1):119-126
Effect of gene­tic poly­morphisms on the effe­ctiveness and safety of sodium-glucose co-transporter 2 inhi­bitors in treatment of type 2 diabetes mellitus. Russian Journal of Preventive Medi­cine. 2024;(1):67-71

Keywords:

diabetes mellitus type II
surgical treatment
glucose homeostasis
insulin resistance
indications to the surgeries for diabetes mellitus type II

Authors:

Sazhin A.V.

Pirogov Russian National Research Medical University

Khusyainova A.I.

Department of faculty surgery named after S.I. Spasokukotskyi, School of general medicine, Pirogov Russian National Research Medical University, Moscow, Russia

Petukhov V.A.

Department of faculty surgery named after S.I. Spasokukotskyi, School of general medicine, Pirogov Russian National Research Medical University, Moscow, Russia

List of references:

  1. Dixon J, O’Brien P, Playfair J. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008;299:316-323.
  2. Courcoulas A, Goodpaster B, Eagleton J. Surgical vs medical treatments for type 2 diabetes mellitus: a randomized clinical trial. JAMA Surg. 2014;149:707-715.
  3. Halperin F, Ding S, Simonson D. Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial. JAMA Surg. 2014;149:716-726.
  4. Ikramuddin S, Korner J, Lee W. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA. 2013;309:2240-2249.
  5. Mingrone G, Panunzi S, De Gaetano A. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366:1577-1585.
  6. Schauer P, Kashyap S, Wolski K. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366:1567-1576.
  7. Keating C, Neovius M, Sjöholm K. Health-care costs over 15 years after bariatric surgery for patients with different baseline glucose status: results from the Swedish Obese Subjects study. Lancet Diabetes Endocrinol. 2015;3:855-865.
  8. Picot J, Jones J, Colquitt J. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess. 2009;13:1-190, 215-357.
  9. Cummings D, Cohen R. Beyond BMI: the need for new guidelines governing the use of bariatric and metabolic surgery. Lancet Diabetes Endocrinol. 2014;2:175-181. https://doi.org/10.3390/microorganisms3040641
  10. Kasama K, Mui W, Lee W. IFSO-APC consensus statements 2011. Obes Surg. 2012;22:677-684.
  11. Young M, Gebhart A, Phelan M, Nguyen N. Use and outcomes of laparoscopic sleeve gastrectomy vs laparoscopic gastric bypass: analysis of the American college of surgeons NSQIP. J Am Coll Surg. 2015;220:880-885.
  12. Rubino F, David M, Robert H, Philip R, George M, Paul Z, Del Prato S, Linong J, Shaukat M, William H, Stephanie A, Lee M, Taroncher-Oldenburg G, David E. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care. 2016;39(6): 861-877. https://doi.org/10.2337/dc16-0236
  13. Burns P, Rohrich R, Chung K. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011;128: 305-310.
  14. Shekelle P, Woolf S, Eccles M, Grimshaw J. Developing clinical guidelines. West J Med. 1999;170:348-351.
  15. Carlsson L, Peltonen M, Ahlin S. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012; 367:695-704.
  16. Aminian A, Brethauer S, Kirwan J, Kashyap S, Burguera B, Schauer P. How safe is metabolic/diabetes surgery? Diabetes Obes Metab. 2015;17:198-201.
  17. Arterburn D, Courcoulas A. Bariatric surgery for obesity and metabolic conditions in adults. BMJ. 2014;349:3961.
  18. Courcoulas A, Christian N, Belle S. Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. JAMA. 2013;310:2416-2425.
  19. Flum D, Belle S, King W. Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med. 2009;361:445-454.
  20. Sjöström L, Peltonen M, Jacobson P. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307:56-65.
  21. Adams T, Davidson L, Litwin S. Health benefits of gastric bypass surgery after 6 years. JAMA. 2012;308:1122-1131.
  22. Panunzi S, Carlsson L, De Gaetano A. Determinants of diabetes remission and glycemic control after bariatric surgery. Diabetes Care. 2016;39:166-174.
  23. Mingrone G, Panunzi S, De Gaetano A. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015;386:964-973.
  24. Clements R, Gonzalez Q, Long C, Wittert G, Laws H. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus. Am Surg. 2004;70:1-4; discussion 5.
  25. Cohen R, Pinheiro J, Schiavon C, Salles J, Wajchenberg B, Cummings D. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care. 2012;35:1420-1428.
  26. Leyton O. Diabetes and operation: a note on the effect of gastrojejunostomy upon a case of mild diabetes mellitus with a low renal threshold. Lancet. 1925;206:1162-1163.
  27. Sjöholm K, Pajunen P, Jacobson P. Incidence and remission of type 2 diabetes in relation to degree of obesity at baseline and 2 year weight change: the Swedish Obese Subjects (SOS) study. Diabetologia. 2015;58:1448-1453.
  28. Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273:219-234.
  29. Boutagy N, McMillan R, Frisard M, Hulver M. Metabolic endotoxemia with obesity: Is it real and is it relevant? Biochimie. 2016;124:11-20. Epub 2015 Jun 29. https://doi.org/10.1016/j.biochi.2015.06.020
  30. Knop F, Taylor R. Mechanism of Metabolic Advantages After Bariatric Surgery. Diabetes Care. 2013; 36(suppl 2):287-291. https://doi.org/10.2337/dcS13-2032
  31. Krasner N, Ido Y, Ruderman N, Cacicedo J. Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation through a Calcium and AMPK Dependent Mechanism. PLoS One. 2014;9(5):97554. https://doi.org/10.1371/journal.pone.0097554
  32. Papasavas P, Stone A, Ajayi O, Muddasani K, Tishler D. Gastric bypass surgery as treatment of recalcitrant gastroparesis. Surg Obes Relat Dis. 2014;10(5):795-799. https://doi.org/10.1016/j.soard.2014.01.013
  33. Shehab M, Al-Dahr M. Weight loss improves biomarkers endothelial function and systemic inflammation in obese postmenopausal Saudi women. Afr Health Sci. 2016;16(2):533-541. https://doi.org/10.4314/ahs.v16i2.22
  34. Buchwald H, Avidor Y, Braunwald E, Jensen M, Pories W, Fahrbach K, Schoelles K. Bariatric surgery: a systematic review and meta-analysis. JAMA. 200413;292(14):1724-1737.
  35. Baltasar A, Serra C, Perez N, Bou R, Bengochea M, Ferri L. Laparoscopic sleeve gastrectomy: a multi-purpose bariatric operation. Obes Surg. 2005;15:1124-1128.
  36. Santoro S, Malzoni C, Velhote M, Milleo F, Santo M, Klajner S, Damiani D, Maksoud J. Digestive Adaptation with Intestinal Reserve: a neuroendocrine-based operation for morbid obesity. Obes Surg. 2006;16:1371-1379.
  37. Santoro S, Velhote M, Malzoni C, Milleo F, Klajner S, Campos F. Preliminary results from digestive adaptation: a new surgical proposal for treating obesity, based on physiology and evolution. Sao Paulo Med J. 2006;124:192-197.
  38. Rubino F, Gagner M, Gentileschi P, Kini S, Fukuyama S, Feng J, Diamond E. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg. 2004;240:236-242.
  39. Schauer P, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hamad G, Eid G, Mattar S, Ramanathan R, Barinas-Mitchel E, Rao R, Kuller L, Kelley D. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238:467-484; discussion 484-485.
  40. Stearns A, Balakrishnan A, Tavakkolizadeh A. Impact of Roux-en-Y gastric bypass surgery on rat intestinal glucose transport. Am J Physiol Gastrointest Liver Physiol. 2009;297:950-957.
  41. Chandarana K, Drew M, Emmanuel J, Karra E, Gelegen C, Chan P, Cron N, Batterham R. Subject standardization, acclimatization, and sample processing affect gut hormone levels and appetite in humans. Gastroenterology. 2009;136:2115-2126.
  42. Patti M, Houten S, Bianco A, Bernier R, Larsen P, Holst J, Badman M, Maratos-Flier E, Mun E, Pihlajamaki J, Auwerx J, Goldfine A. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring). 2009;17:1671-1677.
  43. Cummings D, Overduin J, Foster-Schubert K. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab. 2004;89:2608-2615.
  44. Nandagopal R, Brown R, Rother K. Resolution of Type 2 Diabetes Following Bariatric Surgery: Implications for Adults and Adolescents. Diabetes Technol Ther. 2010;12(8): 671-677. https://doi.org/10.1089/dia.2010.0037
  45. Rubino F. Bariatric surgery: effects on glucose homeostasis. Curr Opin Clin Nutr Metab Care. 2006;9:497-507;pmid:16778583.
  46. Rubino F, Forgione A, Cummings D. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244:741-749;pmid:17060767.
  47. Rubino F, Kaplan L, Schauer P, Cummings D. Diabetes Surgery Summit Delegates. The Diabetes Surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg. 2010;251:399-405;pmid:19934752.
  48. Rubino F, Schauer P, Kaplan L, Cummings D. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med. 2010;61:393-411;pmid:20059345.
  49. Dirksen C, Jørgensen N, Bojsen-Møller K. Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. Diabetologia. 2012;55:1890-1901;pmid:22538359.
  50. Holst J. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409-1439;pmid:17928588.
  51. Laferrère B, Teixeira J, McGinty J. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:2479-2485;pmid:18430778.
  52. Dirksen C, Hansen D, Madsbad S. Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion: a case report. Diabetes Care. 2010;33:375-377;pmid:19918005.
  53. Cummings D. Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery. International Journal of Obesity. 2009;33:33-40. https://doi.org/10.1038/ijo.2009.15
  54. Cummings D, Flum D. Gastrointestinal surgery as a treatment for diabetes. JAMA. 2008;299:341-343.
  55. Cummings D, Foster-Schubert K, Carlson M, Shannon M, Overduin J. Possible hormonal mechanisms mediating the effects of bariatric surgery. In: Pitombo C (ed). Obesity Surgery: Principle and Practice. New York: McGraw-Hill; 2007
  56. Cummings D. Gastric bypass and nesidioblastosis — too much of a good thing for islets? N Engl J Med. 2005;353:300.
  57. Cummings D, Overduin J, Foster-Schubert K, Carlson M. Role of the bypassed proximal intestine in the anti-diabetic effects of bariatric surgery. Surg Obes Relat Dis. 2007;3:109-115.
  58. Cummings D, Overduin J, Shannon M, Foster-Schubert K. Hormonal mechanisms of weight loss and diabetes resolution after bariatric surgery. Surg Obes Relat Dis. 2005;1:358-368:302.
  59. Cummings D, Shannon M. Ghrelin and gastric bypass: is there a hormonal contribution to surgical weight loss? J Clin Endocrinol Metab. 2003;88:2999-3002.
  60. Cummings D, Weigle D, Frayo R, Breen P, Dellinger E. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346:1623-1630.
  61. Goldfine A, Mun E, Devine E, Bernier R, Baz-Hecht M, Jones D. Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. J Clin Endocrinol Meta. 2007;92:4678-4685.
  62. De Paula A, Macedo A, Prudente A, Queiroz L, Schraibman V, Pinus J. Laparoscopic sleeve gastrectomy with ileal interposition (‘neuroendocrine brake’)—pilot study of a new operation. Surg Obes Relat Dis. 2006;2:464-467.
  63. Patriti A, Aisa M, Annetti C, Sidoni A, Galli F, Ferri I. How the hindgut can cure type 2 diabetes. Ileal transposition improves glucose metabolism and beta-cell function in Goto — kakizaki rats through an enhanced proglucagon gene expression and L-cell number. Surgery. 2007;142:74-85.
  64. Patriti A, Facchiano E, Annetti C, Aisa M, Galli J, Fanelli C. Early improvement of glucose tolerance after ileal transpositition in a non-obese type 2 diabetes rat model. Obes Surg. 2005;15:1258-1264.
  65. Rubino F, Marescaux J. Effect of duodenal — jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg. 2004;239:1-11.
  66. Gupta R, Chamany T, Makam R. Does length of common limb influence remission of diabetes? Short-term results. J Minim Access Surg. 2016;12(1):54-57. https://doi.org/10.4103/0972-9941.152104
  67. Fishman M. Justification and assessment of the effectiveness of surgical treatment of patients with obesity, metabolic syndrome and its complications: Dis... doctor med. science. Saint-Petersburg. 2008.
  68. Peterli R, Wölnerhanssen B, Peters T, Devaux N, Kern B, Christoffel-Courtin C, Drewe J, von Flüe M, Beglinger C. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg. 2009; 250(2):234-241. https://doi.org/10.1097/SLA.0b013e3181ae32e3
  69. Lee W, Wang W, Lee Y, Huang M, Ser K, Chen J. Effect of laparoscopic mini-gastric bypass for type 2 diabetes mellitus: comparison of BMI>35 and <35 kg/m2. J Gastrointest Surg. 2008; 12(5):945-952.
  70. Buchwald H, Estok R, Fahrbach K, Banel D, Michael D, Walter J, Bantle J, Sledge I. Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis. 2009;122(3):248-256. https://doi.org/10.1111/j.1476-5381.2011.01561.x
  71. Lee W, Chong K, Ser K, Lee Y, Chen S, Chen J, Tsai M, Chuang L. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg. 2011;146(2):143-148. https://doi.org/10.1001/archsurg.2010.326
  72. Goel R, Pravin A, Madhu G, Sanjeet M. Early remission of type 2 diabetes mellitus by laparoscopic ileal transposition with sleeve gastrectomy surgery in 23-35 BMI patients. International Journal of Diabetes in Developing Countries. 2011;31:2:91-96.
  73. Strader A, Torsten P, Ronald J, Stephen C, D’Alessio D, Randy J. Seeley Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. American Journal of Physiology —Endocrinology and Metabolism Published. 2005;288:2:447-453. https://doi.org/10.1152/ajpendo.00153.2004
  74. Dixon J, Lambert E, Lambert G. Neuroendocrine adaptations to bariatric surgery. Mol Cell Endocrinol. 2015;418:2:143-152. Epub 2015 Jun 1. https://doi.org/10.1016/j.mce.2015.05.033
  75. Buchwald H, Estok R, Fahrbach K. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248-256;e5pmid: 19272486.
  76. Schauer P, Ikramuddin S. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238:467-484; discussion 84-85;pmid:14530719.
  77. Sjöström L, Lindroos A, Peltonen M. Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683-2693; pmid:15616203.
  78. Young M, Gebhart A, Phelan M, Nguyen N. Use and outcomes of laparoscopic sleeve gastrectomy vs laparoscopic gastric bypass: analysis of the American college of surgeons NSQIP. J Am Coll Surg. 2015;220:880-885.
  79. Bays H, Cohen D. Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2007;23:1673-1684.
  80. Larsson E, Tremaroli V, Lee Y, Koren O, Nookaew I, Fricker A, Nielsen J, Ley R, Bäckhed F. Analysis of gut microbial regulation of host gene expression along the length of the gut and regulation of gut microbial ecology through MyD88. Gut. 2012;61(8):1124-1131. Epub 2011 Nov 23. https://doi.org/10.1136/gutjnl-2011-301104
  81. Parker H, Wallis K, Roux C, Wong K, Reimann F, Gribble F. Molecular mechanism underlying bile acid stimulated glucagon-like peptide-1 secretion. Br J Pharmacol. 2011. https://doi.org/10.1111/j.1476-5381.2011.01561.x
  82. Watanabe M, Houten S, Wang L. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest. 2004;113:1408-1418.
  83. Watanabe M, Houten S, Mataki C. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006;439:484-489.
  84. Werling M, Vincent R, Cross G, Hanns-Ulrich M, Fändriks L, Lönroth H, Taylor D, Alaghband-Zadeh J, Olbers T, Le Roux C. Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery. Scandinavian Journal of Gastroenterology. 2013;48(11):1257-1264. https://doi.org/10.3109/00365521.2013.833647
  85. Vinolo M, Rodrigues H, Nachbar R, Curi R. Regulation of Inflammation by Short Chain Fatty Acids. Nutrients. 2011;3:858-876. https://doi.org/10.3390/nu3100858
  86. Jiménez A, Casamitjana R, Viaplana-Masclans J, Lacy A, Vidal J. GLP-1 action and glucose tolerance in subjects with remission of type 2 diabetes after gastric bypass surgery. Diabetes Care. 2013;36(7):2062-2069. https://doi.org/10.2337/dc12-1535
  87. Raffaelli M, Guidone C, Callari C, Amerigo I, Rocco B, Geltrude M. Effect of Gastric Bypass Versus Diet on Cardiovascular Risk Factors. Annals of Surgery. 2014;259:4:694-699. https://doi.org/10.1097/SLA.0b013e31829d6989
  88. Joshua B, Laferrère B, Cummings B. Tri-Point Series: A Road to Remission: Multiple Perspectives of Bariatric Surgery and Its Effects on Metabolic Disease. Clinical Endocrinology Update APR. 2015;21-26.
  89. Alam M, Van der Schueren B, Ahren B, Wang G, Swerdlow N, Arias S, Bose M, Gorroochurn P, Teixeira J, McGinty J, Laferrère B. Gastric bypass surgery, but not caloric restriction, decreases dipeptidyl peptidase-4 activity in obese patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(4):378-381. https://doi.org/10.1111/j.1463-1326.2011.01358.x
  90. Adrian T, Ballantyne G, Longo W, Bilchik A, Graham S, Basson M, Tierney R, Modlin I. Deoxycholate is an important releaser of peptide YY and enteroglucagon from the human colon. Gut. 1993;34:1219-1224. https://doi.org/10.1136/gut.34.9.1219
  91. Adrian T, Gariballa S, Parekh K, Thomas S, Saadi H, Kaabi J, Nagelkerke N, Gedulin B, Young A. Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers. 2012;55(9):2343-2347. https://doi.org/10.1007/s00125-012-2593-2
  92. Wu T, Bound M, Standfield S, Gedulin B, Jones K, Horowitz M, Rayner C. Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans. Diabetes Obes Metab. 2013;15(5):474-477. https://doi.org/10.1111/dom.12043
  93. Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, Prifti E, Vieira-Silva S, Gudmundsdottir V, Krogh P, Arumugam M, Kristiansen K, Voigt A, Vestergaard H, Hercog R, Igor C, Kultima J, Li J, Jоrgensen T, Levenez F, Dore J, Nielsen H, Brunak S, Raes J, Hansen T, Wang J, Ehrlich S, Bork P, Pedersen O. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015;528(7581):262-266. https://doi.org/10.1038/nature15766
  94. Jia V, Ashrafian H, Bueter M, Kinross J, Sands C, le Roux C, Bloom S, Darzi A, Athanasiou T, Marchesi J, Nicholson J, Holmes E. Metabolic Surgery Profoundly Influences Gut Microbial-Host Metabolic Crosstalk. Gut. 2011;60(9):1214-1223. https://doi.org/10.1136/gut.2010.234708
  95. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun. 2005;329(1):386-390.
  96. Kootte R, Vrieze A, Holleman F, Dallinga-Thie G, Zoetendal E, de Vos W, Groen A, Hoekstra J, Stroes E, Nieuwdorp M. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14(2):112-120. https://doi.org/10.1111/j.1463-1326.2011.01483.x
  97. Cani P, Amar J, Iglesias M, Poggi M, Knauf C, Bastelica D, Neyrinck A, Fava F, Tuohy K, Chabo C, Waget A, Delmée E, Cousin B, Sulpice T, Chamontin B, Ferrières J, Tanti J, Gibson G, Casteilla L, Delzenne N, Alessi M, Burcelin R. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761-172. Epub 2007 Apr 24.
  98. Lewis K, Lutgendorff F, Phan V, Söderholm J, Sherman P, McKay D. Enhanced translocation of bacteria across metabolically stressed epithelia is reduced by butyrate. Inflamm Bowel Dis. 2010;16(7):1138-1148. https://doi.org/10.1002/ibd.21177
  99. Torsten P, Dallinga-Thie G, de Vos W, Nieuwdorp M, van Raalte D. Causality of small and large intestinal microbiota in weight regulation and insulin resistance. Mol Metab. 20165(9):759-770. https://doi.org/10.1016/j.molmet.2016.06.002
  100. Rubino F. Medical research: Time to think differently about diabetes. New guidelines for the surgical treatment of type 2 diabetes bolster hopes of finding a cure, writes Francesco Rubino, but long-standing preconceptions must be put aside. Nature Comment. 2016;533:459-461. https://doi.org/10.1038/539029
  101. Savelyev V, Petukhov V. A new method for the treatment of disorders of the liver function in type 2 diabetes and diabetic angiopathy. Difficult patient. 2004;2:5:24-30.
  102. John Y. Bile Acid Metabolism and Signaling. Compr Physiol. 2013;3(3):1191-1212. https://doi.org/10.1002/cphy.c120023
  103. Baars A, Oosting A, Knol J, Garssen J, van Bergenhenegouwen J. The Gut Microbiota as a Therapeutic Target in IBD and Metabolic Disease: A Role for the Bile Acid Receptors FXR and TGR5. Microorganisms. 2015;3(4):641-666. https://doi.org/10.3390/microorganisms3040641
  104. Buchwald H, Varco R, Matts J, Long J, EdD, Fitch L, Campbell G, Pearce M, Yellin A, Edmiston W, Smink R, Sawin H, Campos C, Hansen B, Tuna N, Karnegis J, Sanmarco M, Amplatz K, Castaneda-Zuniga W, Hunter D, Bissett J, Weber F, Stevenson J, Leon A, Chalmers T. Effect of Partial Ileal Bypass Surgery on Mortality and Morbidity from Coronary Heart Disease in Patients with Hypercholesterolemia — Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990;323:946-955. October 4, 1990. https://doi.org/10.1056/NEJM199010043231404

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.